Vor Biopharma Inc (VOR)
Vor Biopharma Inc. is a clinical-stage cell and genome engineering company focused on developing therapies for acute myeloid leukemia and other blood cancers. Its main platform, the Vor Bio platform, supports a pipeline that includes tremtelectogene empogeditemcel, or trem-cel, a genome-edited allogeneic stem and progenitor cell product candidate being studied for AML, myelodysplastic syndrome, and related blood cancers. The company is also evaluating trem-cel with Mylotarg in the phase 1/2 VBP101 study, while its VCAR33 program is a preclinical CAR-T therapy designed to target CD33 in AML after transplant. Additional preclinical programs include trem-cel plus VCAR33, VADC45 for hematologic malignancies, conditioning and immune reset, and a CD33-CLL1 treatment system based on multiplex-edited HSC and multi-specific CAR-T approaches. Vor Biopharma was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VOR
|
$18.30
|
-3.2% Downside
|
Fair
|
$37.88
|
100.3% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-1.2x
|
-6.8x
|
—
|
945.5 M
|
535.8 M
|
0.3%
|
74.1%
|
-4.0
|
—
|
17.1%
|
